Sunitinib

2019: Nativa confirmed the right to production of a domestic sunitinib

On April 22, 2019 the Nativa company reported that the Ninth arbitration Court of Appeal confirmed the decision of Arbitration court of Moscow of February 8, 2019 on providing to the Russian company the license to use of the patent of the "Pharmassia Enda Apdjon of Kampeni" company entering, according to her representatives, in Pfizer group. The license is granted to the Russian producer in connection with existence of a dependent invention which the Nativa company is going to apply by production of own development "Sunitinib-nativ", medicine with active agent sunitinib. Undertook to pay for use of the patent of Nativa LLC to an originator license fees.

It is the another system victory of our company in court. The right to production of completely domestic sunitinib is confirmed in the first and second judicial authorities. We have all bases to speak about production and implementation of medicine for treatment of a serious oncological illness on legal grounds. Alexander Malin, CEO of Nativa LLC

The Court of Appeal confirmed the decision of Arbitration court of Moscow of February 8, 2019 on removal of charges of violation of the exclusive right to the invention protected by the Eurasian patent No. 005996 and also on providing the simple non-exclusive license on use of this patent. It is about an opportunity to make, apply, sell and store the medicines containing in quality of active agent sunitinib on the terms of payment of license fees.

Antineoplastic active agent sunitinib represents inhibitor about 80 enzymes participating in growth of a malignant tumor, in education a metastasis and pathological angiogenesis is applied to treatment of the kidney and cellular cancer (KCC) and a pancreatic cancer. On incidence among malignant new growths of an urinogenital system after tumors of a prostate gland and bladder, PKR in Russia takes the 3rd place. Annually about 24 thousand cases are registered, the rate of a gain exceeds 25%. Since 2016 death rate recession is observed that is explained by early diagnostics and improvement of treatment of the Russian patients late stages of a disease. The average indicator of death rate of the Russian patients from malignant tumors of a kidney is 3.34 on 100 thousand population. The cost of the reproduced medicine is lower than an originator for 26%. Medicine is included in the list of the ZhVNLP federal program.

This second decision on licensing for a dependent invention on the account of the Russian company. Earlier Nativa obtained the license to use of the patent of the American corporation "Seldzhen" for medicine with active ingredient lenalidomid. However based on the settlement agreement of the party came to the mutually advantageous agreement, and Nativa did not exercise the right to use the license of this type.